The estimated Net Worth of Science Biosensor Diagnosti... is at least $7.4 Milion dollars as of 17 February 2022. Science Diagnosti owns over 576,028 units of GBS stock worth over $508,448 and over the last 4 years Science sold GBS stock worth over $6,891,194.
Sign up
Science Diagnosti GBS stock SEC Form 4 insiders trading
Science has made over 29 trades of the GBS stock since 2021, according to the Form 4 filled with the SEC. Most recently Science sold 576,028 units of GBS stock worth $293,774 on 17 February 2022.
The largest trade Science's ever made was selling 576,028 units of GBS stock on 17 February 2022 worth over $293,774. On average, Science trades about 140,653 units every 5 days since 2021. As of 17 February 2022 Science still owns at least 1,081,804 units of GBS stock.
You can see the complete history of Science Diagnosti stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Science Diagnosti's mailing address?
Science's mailing address filed with the SEC is LEVEL 9, 85 CASTLEREAGH ST, , SYDNEY, C3, 2000.
Insiders trading at GBS
Over the last 4 years, insiders at GBS have traded over $6,891,194 worth of GBS stock and bought 51,106 units worth $85,007 . The most active insiders traders include Science Biosensor Diagnosti..., Spiro Kevin Sakiris oraz Tom Parmakellis. On average, GBS executives and independent directors trade stock every 12 days with the average trade being worth of $51,467. The most recent stock trade was executed by Spiro Kevin Sakiris on 22 June 2022, trading 5,000 units of GBS stock currently worth $3,250.
What does GBS do?
GBS Inc. operates as a biosensor diagnostic technology company. It offers Saliva Glucose Biosensor that uses saliva to measure glucose non-invasively. The company also focuses on developing COV2 test, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumour markers, hormones, and nucleic acid diagnostic modalities. It has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
What does GBS's logo look like?
Complete history of Science Diagnosti stock trades at GBS
GBS executives and stock owners
GBS executives and other stock owners filed with the SEC include:
-
Harry Simeonidis,
Pres of Asia Pacific - Sales & Marketing -
Spiro Kevin Sakiris B.Bus, C.A., CA, Dip Law,
Chief Financial Officer -
Spiro Kevin Sakiris C.A., B.Bus, Dip Law, CA,
Chief Financial Officer -
Dr. Stephen Constantine Boyages M.D., MBBS, Ph.D.,
Interim CEO & Chairman -
Joe Roxburgh,
Non-Executive Director -
Steven Ross,
Non-Executive Director -
Christopher Foulds,
Non-Executive Director -
Graham Tuckwell,
Non-Executive Chairman of the Board -
Alex Arzeno,
VP of Investor Relations -
Victoria Gavrilenko,
Operations Mang. -
Spiro Kevin Sakiris,
Chief Financial Officer -
Harry Simeonidis,
President -
Lawrence B Fisher,
Director -
George Margelis,
Director -
Jonathan Scott Hurd,
Director -
Steven Constantine Boyages,
Interim CEO and Chairperson -
Tom Parmakellis,
Director -
Science Biosensor Diagnosti...,
-
Victoria Gavrilenko,
Director -
Christopher Towers,
Director